Advances in gene therapy of liver cirrhosis: A review

World Journal of Gastroenterology

Volumn 7, Issue 1, 2001, Pages 1-8

  Dai, W J ^a   Jiang, H C ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; RECOMBINANT INTERLEUKIN 10; SCATTER FACTOR; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA;

CELL REGENERATION; DRUG INHIBITION; DRUG MECHANISM; EXPERIMENTAL MODEL; FIBROGENESIS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; LIVER CIRRHOSIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TELOMERE;

EID: 0035113476     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v7.i1.1     Document Type: Review

References (107)

1. The cellular basis of hepatic fibrosis: Mechanisms and treatment strategies
2. Molecular regulation of hepatic fibrosis, an integrated cellular responses to tissue injury
3. Hepatic fibrosis as wound repair: A progress report
4. A comparative study of fat storing cells and hepatocytes in collagen synthesis and collagen gene expression
5. Transforming growth factor β in tissue fibrosis
6. Gene therapy of hepatic diseases: Prospects for the new millennium
7. Gene therapy for hepatic fibrosis-bringing treatment into the new millennium
8. Transforming growth factor-β gene expression in normal and fibrotic rat liver
9. Role of transforming growth factor betal in hepatic fibrosis
10. Transforming growth factor-β signaling and cirrhosis
11. Acetaldehyde regulates the gene expression of matrix-metalloproteinase-1 and -2 in human fat-storing cells
12. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver
13. Dynamic changes of gelatinase A gene expression in the course of experimental hepatic fibrosis
14. Transcriptional mechanisms of type I collagen gene expression are differentially regulated by interleukin-1 β, tumor necrosis factor α, and transforming growth factor β in Ito cells
15. 1 in human fat-storing cells
16. Synthesis of cellular fibronectin by rat liver fat-storing (Ito) cells: Regulation by cytokines
17. 1 on Ito cell
18. Modulation of transforming growth factor β receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo
19. Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor
20. Expression of mRNAs for transforming growth factor-β receptors in the rat testis
21. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat
22. Adenovirus-mediated transfer of a truncated transforming growth factor-β (TGF-β) type II receptor completely and specifically abolishes diverse signaling by TGF-β in vascular wall cells in primary culture
23. Inhibition of PDGFβ receptor signal transduction by coexpression of a truncated receptor
24. A soluble transforming growth factor β receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats
25. Action of cell factor and decorin in tissue fibrosis
26. A transforming growth factor β type I receptor that signals to activate gene expression
27. Mechanism of activation of the TGF-β receptor
28. Distinct roles of the intracellular domains of transforming growth factor-β type I and type II receptors in signal transduction
29. Signaling activity of homologous and heterologous transforming growth factor-β receptor kinase complexes
30. A dominant-negative receptor for type β transforming growth factors created by deletion of the kinase domain
31. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities
32. Dominant-negative mutations of platelet-derived growth factor (PDGF) receptors. Inhibition of receptor function by ligand-dependent formation of heterodimers between PDGF α - and β- receptors
33. Fibroblast growth factor receptor is required for in vivo cardiac myocyte proliferation at early embryonic stages of heart development
34. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
35. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
36. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
37. A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor
38. 1 gene results in multifocal inflammatory disease
39. Liver regeneration
40. Liver regeneration
41. The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis
42. Hepatocyte growth factor: Mesenchymal signal for epithelial homeostasis
43. Expression of local hepatocyte growth factor system in vascular tissues
44. Hepatocyte growth factor and its receptor c-met in multiple myeloma
45. Hepatocyte growth factor mRNA in human liver cirrhosis as evidenced by in situ hybridization
46. Involvement of hepatocyte growth factor in formation of bronchoalveolar structures in embryonic rat lung in primary culture
47. Hepatocyte growth fuctor
48. Hepatocyte growth factor in transgenic mice: Effects on hepatocyte growth, liver regeneration and gene expression
49. Intravenous injection of an adenovirus encoding hepatocyte growth factor results in liver growth and has a protective effect against apoptosis
50. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats
51. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-β
52. Anti-hepatocyte growth factor antibody inhibits hepatocyte proliferation during liver regeneration
53. Hepatocyte growth factor gene therapy of liver cirrhosis in rats
54. Current situation in studies of gene therapy for liver cirrhosis and liver fibrosis
55. Reversing liver cirrhosis: Impact of gene therapy for liver cirrhosis
56. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: Up-regulation of essential transcription factor for angiogenesis, ets
57. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences
58. Structural and functional characterization of the mouse hepatocyte growth factor gene promoter
59. Human hepatic stimulator substance: A product of gene expression of human fetal liver tissue
60. Cloning and sequence analysis of the rat augmenter of liver regeneration (ALR) gene: Expression of biologically active recombinant ALR and demonstration of tissue distribution
61. Studies on chemicophysical properties of recombinant human hepatopoietin
62. Isolation and sequence analysis of the human augmenter of liver regeneration
63. Molecular cloning of new type augmenter of liver regeneration and research on its function
64. Cloning and sequencing of rat and human augmenter of liver regeneration gene
65. The cDNA clone and sequence analysis of the coding region of human augmenter of liver regeneration (hALR) gene
66. Identification and characterization of receptor for mammalian hepatopoietin that is homologous to yeast ERV1
67. A fresh look at augmenter of liver regeneration in rats
68. On the cell biology of pit cells, the liver-specific NK cells
69. The in vivo effect of hepatotrophic factors augmenter of liver regeneration, hepatocyte growth factor, and insulin-like growth factor-II on liver natural killer cell functions
70. Molecular mechanisms of augmenter of liver regeneration as immunoregulator: Its effect on interferon-γ expression in rat liver
71. The augmenter of liver regeneration induces mitochondrial gene expression in rat liver and enhances oxidative phosphorylation capacity of liver mitochondria
72. Cloning and expression of rat augmenter of liver regeneration
73. Protection of recombinant human augmenter of liver regeneration to experimental hepatic fibrosis in rats
74. Effects of augmenter of liver regeneration on liver proliferation and anti-injury
75. Biological properties of interleukin 10
76. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1
77. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis
78. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice
79. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells
80. Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation in vitro
81. Kupffer cell depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis factor alpha messenger RNA in the regenerating rat liver
82. 2MDP-liposomes alters hepatic cytokine expression and delays liver regeneration after partial hepatectomy
83. Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholic cirrhosis
84. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts
85. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes
86. Interleukin 10 inhibits transforming growth factor-β (TGF-β) synthesis required for osteogenic commitment of mouse bone marrow cells
87. Interleukin-10 attenuates the release of proinflammatory cytokines but depresses splenocyte functions in murine endotoxemia
88. Downregulation of cytokine-induced neutrophil chemoattractant and prolongation of rat liver allograft survival by interleukin-10
89. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice
90. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis
91. Induction of the chemokine β peptides, MIP-1 α and MIP-1β, by lipopolysaccharide is differentially regulated by immunomodulatory cytokines γ-IFN, IL-10, IL-4 and TGF-β
92. Is interleukin-10 antifibrogenic in chronic liver injury?
93. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
94. Telomere, telomerase and digestive cancer
95. Telomerase activity in normal leukocytes and in hematologic malignancies
96. Telomere length in human liver diseases
97. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis
98. Telomerase activity of needle-biopsied liver samples: Its usefulness for diagnosis and judgment of efficacy of treatment of small hepatocellular carcinoma
99. Quantitative analysis and in situ localization of human telomerase RNA in chronic liver disease and hepatocellular carcinoma
100. Quantitative evaluation of telomerase activity in small liver tumors: Analysis of ultrasonography-guided liver biopsy specimens
101. Telomerase activity in precancerous hepatic nodules
102. Extension of life-span by introduction of telomerase into normal human cells
103. INK4a inactivation and telomerase activity are required to immortalize human epithelial cells
104. Essential role of mouse telomerase in highly proliferative organs
105. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA
106. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery
107. New genetic tricks to rejuvenate ailing livers